血小板生成素治疗小鼠烧伤合并烟雾吸入性损伤的实验研究
该研究将雌性C57BL/6小鼠制成30%TBSA全层烧伤合并烟雾吸入性损伤模型,随机分为损伤对照组、rhTPO皮下注射组和雾化吸入组,伤后0.5小时起治疗3天。两种给药途径均改善120小时生存率、提高血小板计数并改善部分血栓弹力图参数,后期肺损伤评分降低、呼吸参数改善,IL-1β和TNF-α降低。
要点
- rhTPO皮下注射或雾化吸入均改善烧伤合并烟雾吸入伤小鼠120小时生存率
- 两种途径均提高血小板计数并改善部分血栓弹力图参数
- 后期肺损伤评分降低、呼吸参数改善,IL-1β和TNF-α降低但IL-6变化不一致
核心结论
- 在小鼠烧伤合并烟雾吸入性损伤模型中,rhTPO经全身或吸入途径给药改善了生存率及多项生理和组织学结局。
- 因缺乏健康/假手术对照组及血小板活化、肺微血栓、rhTPO药代动力学直接检测,结果应视为治疗相关性证据而非明确抗炎机制证明。
研究设计与样本
- 雌性C57BL/6小鼠接受30%TBSA全层烧伤合并烟雾吸入性损伤。
- 小鼠随机分为损伤-only对照组、rhTPO皮下注射组(SIG)和rhTPO雾化吸入组(NIG)。
- 伤后0.5小时开始治疗并持续3天,观察120小时生存率、动脉血气、血小板计数、血栓弹力图、肺组织病理评分、全身体积描记肺功能及肺细胞因子谱。
主要发现
- 两种rhTPO给药途径均改善120小时生存率、提高血小板计数并改善部分血栓弹力图参数。
- H&E组织学评估显示后期时间点肺损伤评分降低,全身体积描记呼吸参数至120小时改善。
- rhTPO治疗组IL-1β和TNF-α水平较低,而IL-6未见一致下降,需谨慎解读。
临床怎么用
- 该动物实验提示rhTPO皮下注射或雾化吸入可能作为烧伤合并烟雾吸入性损伤后改善血小板相关恢复的候选策略。
- 临床转化前需进一步研究明确rhTPO的最佳给药途径、剂量及对血小板活化、肺微血栓和药代动力学的影响。
局限性
- 研究未设健康/假手术对照组。
- 未直接检测血小板活化、肺微血栓或rhTPO药代动力学。
- IL-6未见一致下降,相关结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Burn injuries complicated by smoke inhalation significantly increase clinical severity and can lead to acute respiratory distress syndrome (ARDS). Inhalation injury is predominantly caused by exposure to toxic combustion gases, with thermal damage from steam being relatively uncommon. Thrombocytopenia is frequently observed in severe burns and is associated with poor outcomes, whereas platelet transfusion can carry clinically important risks. Recombinant human thrombopoietin (rhTPO), a hematopoietic growth factor used clinically for thrombocytopenia, may represent an alternative strategy for improving platelet-related recovery after burn-associated inhalation injury. METHODS: Female C57BL/6 mice were subjected to a 30% total body surface area (TBSA) full-thickness burn combined with smoke inhalation injury. Mice were randomized into three groups: injury-only control, rhTPO subcutaneous injection group (SIG), and rhTPO nebulized inhalation group (NIG). Treatments commenced 0.5 h post-injury and continued for 3 days. Outcomes included 120-hour survival, arterial blood gas parameters, platelet count, thromboelastography, lung histopathology scores, plethysmography-based pulmonary function, and lung cytokine profiles. RESULTS: Both rhTPO administration routes improved 120-hour survival, increased platelet counts, and improved selected thromboelastography parameters. H&E-based histological assessment showed lower lung injury scores at later time points, and plethysmography-based respiratory parameters improved by 120 h. IL-1β and TNF-α levels were lower in rhTPO-treated groups, whereas IL-6 did not show a consistent decrease and should be interpreted cautiously. CONCLUSIONS: rhTPO administration, via either systemic or inhaled route, improved survival and several physiological and histological outcomes in this murine model of burn with smoke inhalation injury. Because this study did not include a healthy/sham control group or direct assays of platelet activation, pulmonary microthrombi, or rhTPO pharmacokinetics, the findings should be interpreted as evidence of therapeutic association rather than proof of a defined anti-inflammatory mechanism beyond the measured platelet-related changes.
引用
- Qu Y, Deng Z, Zhou H, et al. Experimental study on the treatment of mouse burn injury combined with smoke inhalation injury using thrombopoietin. Burns. 2026. PMID: 42526204. doi:10.1016/j.burns.2026.108152
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。